Why 'significant upside remains' for CSL shares

Bell Potter thinks very highly of this world-class stock.

| More on:
Two smiling work colleagues discuss an investment or business plan at their office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares could be one of the best options out there for investors right now.

That's the view of analysts at Bell Potter, which have named the biotechnology company on their Australian equities panel this month.

What is an equities panel? It is essentially the broker's best ideas list filled with companies that offer compelling risk/rewards. Bell Potter describes its panel as follows:

Our panel of favoured Australian equities offer attractive risk-adjusted returns over the long term. We consider the current macro-economic backdrop and investment environment, focusing on quality companies with proven track records, strong management teams and competitive advantages.

Why are CSL shares best buys?

Bell Potter highlights that CSL has been a real success story over the past two and a half decades thanks to its ability to generate high returns on capital. It said:

CSL is one of the world's largest global plasma fractionators. The plasma products themselves have proven excellent medical products, with wide application, and deliver therapeutic outcomes difficult to achieve by other means. The company has a proven track record of deploying capital effectively and generating high returns over the past 25 years.

Bell Potter thinks this trend can continue. Particularly given its belief that CSL is entering a margin recovery phase, which it expects to underpin stronger than average earnings growth in the coming years.

And with CSL's shares trading on lower than average multiples, it feels that now could be the time to pounce. The broker explains:

CSL presents an attractive buying opportunity as we anticipate the start of a margin recovery phase for CSL, driving above-market earnings growth over the next few years. CSL trades at a 12-month forward PE of ~28x, representing a discount to its 10-year average of ~31x. Furthermore, the company will continue to deleverage the balance sheet over the next few years. Given the company's proven quality and growth prospects, we believe significant upside remains.

Who else is bullish?

It isn't just Bell Potter that thinks highly of CSL shares. There are a good number of brokers out there that are recommending the company as a buy.

For example, Citi currently has a buy rating and $345.00 price target, Morgans has an add rating and $330.75 price target, and Macquarie has an outperform rating and $330.00 price target, to name just three.

It is also worth noting that Macquarie is so bullish that it believes the CSL share price could rise beyond $500 in the next three years.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two lab workers fist pump each other.
Healthcare Shares

Guess which top 100 ASX stock is venturing off to the Nasdaq

Here’s what’s going on with its United States listing plan.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

Here's why ASX 200 health insurance shares like Medibank are being trounced today

Investors are feeling a bit sick after the latest update.

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Record Highs

Superstar ASX 200 healthcare stock snags record high amid $32 million deal

The second multi-million-dollar deal in less than two weeks.

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Here's why a leading fund manager is excited by this ASX healthcare share

WAM thinks this stock is capable of producing good returns.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
Share Gainers

Guess which ASX biotech stock just rocketed 25% on big US news

Here are all the details.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Fundie bullish on CSL shares after praising the 'special business'

Earnings growth justifies current valuations, these experts say.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Guess which ASX 200 healthcare stock is charging higher following FDA update

What is getting investors excited today? Let's find out.

Read more »

Two happy scientists analysing test results.
52-Week Highs

3 ASX All Ords health care shares that reached 52-week peaks today

These health care companies finished the week on a positive note.

Read more »